Despite this drawback, serum PSA as a continuous variable has been widely used in PCa chemoprevention trials [72–74] as well as in clinical practice, where PSA levels are used to define risk categories [75–78]. The gene discussed is KLK3; the disease is posterior cortical atrophy.